Galectin Therapeutics Inc
F:PHPN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Galectin Therapeutics Inc
F:PHPN
|
US |
|
L
|
L B Foster Co
F:LB1A
|
US |
|
Hatten Land Ltd
SGX:PH0
|
SG |
|
Aquafil SpA
F:6W7
|
IT |
|
L
|
Land Securities Group PLC
F:LSU2
|
UK |
|
K
|
KKR Real Estate Finance Trust Inc
NYSE:KREF
|
US |
|
Gas Plus SpA
LSE:0EMK
|
IT |
|
A
|
Adaptive Biotechnologies Corp
DUS:1HM
|
US |
|
Hci Group Inc
F:0H5
|
US |
|
A
|
Anixa Biosciences Inc
F:CY71
|
US |
|
C
|
Chilwa Minerals Ltd
ASX:CHW
|
AU |
|
A
|
Ad Pepper Media International NV
XMUN:APM
|
DE |
|
B
|
Big Technologies PLC
LSE:BIG
|
UK |
Galectin Therapeutics Inc
Galectin Therapeutics is a biotechnology company that develops medicines aimed at blocking galectin-3, a protein involved in inflammation and fibrosis. Its lead drug candidate is belapectin, which is being studied as a treatment for liver disease tied to scarring and complications of cirrhosis. The company is not a drug seller in the usual sense; it is a development-stage company focused on testing whether its compounds can become approved therapies. The main customers for a company like this are not patients directly, but healthcare providers and, eventually, hospitals and specialty pharmacies if a drug is approved. Galectin Therapeutics makes money mainly through financing and, if its programs succeed, could later earn product sales or licensing revenue. For now, its value depends on advancing clinical trials, securing regulatory approval, and moving a drug from research into the market. What makes the business different is that it is built around a single biological target, galectin-3, rather than a broad drug portfolio. That gives it a very focused strategy: prove that blocking this protein can treat serious fibrotic diseases. In beginner terms, Galectin Therapeutics is a high-risk, research-heavy company trying to turn one scientific idea into a real medicine.
Galectin Therapeutics is a biotechnology company that develops medicines aimed at blocking galectin-3, a protein involved in inflammation and fibrosis. Its lead drug candidate is belapectin, which is being studied as a treatment for liver disease tied to scarring and complications of cirrhosis. The company is not a drug seller in the usual sense; it is a development-stage company focused on testing whether its compounds can become approved therapies.
The main customers for a company like this are not patients directly, but healthcare providers and, eventually, hospitals and specialty pharmacies if a drug is approved. Galectin Therapeutics makes money mainly through financing and, if its programs succeed, could later earn product sales or licensing revenue. For now, its value depends on advancing clinical trials, securing regulatory approval, and moving a drug from research into the market.
What makes the business different is that it is built around a single biological target, galectin-3, rather than a broad drug portfolio. That gives it a very focused strategy: prove that blocking this protein can treat serious fibrotic diseases. In beginner terms, Galectin Therapeutics is a high-risk, research-heavy company trying to turn one scientific idea into a real medicine.
NASH-CX on track: Management said the Phase IIb NASH cirrhosis trial remains on schedule for top-line data in December 2017, with database lock expected around mid-October.
Cash runway: The company ended 2016 with $15.4 million of cash and raised another $1.5 million in early 2017, which management said should fund planned operations through December 31, 2017.
Dropouts better than expected: NASH-CX has had 10 dropouts out of 162 patients, or about 6%, far below the 25% dropout rate assumed in the trial design.
Pipeline focus: Galectin Therapeutics is now focused on NASH cirrhosis, while also exploring skin disease and cancer programs for GR-MD-02 and continuing early work on new galectin inhibitors.
Partnership interest: Management said positive NASH-CX data could trigger partnership discussions, while any skin-disease deal would need to avoid limiting the company’s NASH opportunity.
2017 spending: R&D and G&A expenses are expected to be roughly similar to 2016.
Clinical signals: Management highlighted encouraging early signals in psoriasis, atopic dermatitis, and melanoma combination therapy, but emphasized that these are still preliminary.
